SCHEMBL5198741

SCHEMBL5198741

CC(C)(C)OC(=O)N1C2CCCC1CC2

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.68
CHRM1 P11229 1/20 0.68
CHRM3 P20309 1/20 0.68
PREP P48147 4/20 0.58
HSD11B1 P28845 1/20 0.47
HPGD P15428 1/20 0.44
EPHX1 P07099 1/20 0.41
KAT2B Q92831 1/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTSK P43235 1/20 0.39
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NR1H2 P55055 1/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20635190 1.00 CHRM2 (0.68) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL12345350 1.00 CHRM2 (0.68) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL14545684 0.98 CHRM2 (0.65) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL12461664 0.98 CHRM2 (0.65) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL30968119 0.96 CHRM2 (0.68) CHRM2CHRM1CHRM3PREPHSD11B1
Ammonia Solution, Strong SCHEMBL14919387 0.94 CHRM2 (0.66) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL25010681 0.94 CHRM2 (0.75) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL2123260 0.94 CHRM2 (0.75) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL22341040 0.90 CHRM2 (0.71) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL26251587 0.90 CHRM2 (0.71) CHRM2CHRM1CHRM3PREPHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 US disclosed
CN-116003441-B Heteroaromatic derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2025-06-10 CN disclosed
WO-2025098509-A1 PYRROLIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MEDICINE 康百达(四川)生物医药科技有限公司 2025-05-15 WO disclosed
CN-119350422-B Deubiquitinase targeting chimeric compound and preparation method and application thereof 中国药科大学 2025-04-04 CN disclosed
CN-119638696-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2025-03-18 CN disclosed
CN-119552174-A TLR7 and TLR8 inhibitors, methods of making, pharmaceutical compositions and uses thereof 上海深势唯思科技有限责任公司 2025-03-04 CN disclosed
CN-119528905-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2025-02-28 CN disclosed
CN-119350422-A Deubiquitinase targeting chimeric compound and preparation method and application thereof 中国药科大学 2025-01-24 CN disclosed
WO-2025016273-A1 ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USES OF ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION 拜西欧斯(北京)生物技术有限公司 2025-01-23 WO disclosed
CN-119301113-A Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors 豪夫迈·罗氏有限公司 2025-01-10 CN disclosed
US-8921373-B2 Compounds having TRPV1 antagonistic activity and uses thereof SHIONOGI & CO., LTD. (JP) 2014-12-30 US disclosed
US-20140057895-A1 INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-02-27 US disclosed
US-8623857-B2 N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 MERCK SHARP & DOHME CORP. (US) 2014-01-07 US disclosed
US-20130150342-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 NOVARTIS AG (CH) 2013-06-13 US disclosed
US-20130123239-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF PURDUE PHARMA L.P. 2013-05-16 US disclosed
US-20130079326-A1 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 MERCK SHARP & DOHME CORP. 2013-03-28 US disclosed
US-20110105563-A1 IL-8 RECEPTOR ANTAGONISTS BUSCH-PETERSEN JAKOB 2011-05-05 US disclosed
EP-2241567-A1 BICYCLOAMINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2010-10-20 EP disclosed
EP-1833826-A2 TRICYCLIC DELTA-OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-09-19 EP disclosed
WO-2006069276-A2 TRICYCLIC ō-OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105563-A1 IL-8 RECEPTOR ANTAGONISTS CXCL8, CCR8, IL1RN CHRM2 2688/4885CHRM1 3441/4885CHRM3 1679/4885
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 CHRM2 4596/4885CHRM1 4752/4885CHRM3 4727/4885
US-20130123239-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF TRPV1, TRPA1, TRPV2 CHRM2 1480/4885CHRM1 1579/4885CHRM3 1024/4885
US-20130150342-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 CDK4, CDK6, CCNT1 CHRM2 4019/4885CHRM1 3267/4885CHRM3 4706/4885
US-20140057895-A1 INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF HTR4, HTR3B, HTR3A CHRM2 312/4885CHRM1 199/4885CHRM3 107/4885
US-20130079326-A1 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 PDPK1, PDK1, PDK3 CHRM2 3587/4885CHRM1 3139/4885CHRM3 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.